# Efficacy and Safety of SmofKabiven Extra Nitrogen for Parenteral Nutrition in Patients Receiving Intensive Care

> **NCT05257031** · PHASE3 · COMPLETED · sponsor: **Fresenius Kabi** · enrollment: 56 (actual)

## Conditions studied

- Nutrition Therapy
- Critical Illness

## Interventions

- **DRUG:** SmofKabiven extra Nitrogen

## Key facts

- **NCT ID:** NCT05257031
- **Lead sponsor:** Fresenius Kabi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-02-12
- **Primary completion:** 2022-09-11
- **Final completion:** 2023-06-30
- **Target enrollment:** 56 (ACTUAL)
- **Last updated:** 2024-02-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05257031

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05257031, "Efficacy and Safety of SmofKabiven Extra Nitrogen for Parenteral Nutrition in Patients Receiving Intensive Care". Retrieved via AI Analytics 2026-07-02 from https://api.ai-analytics.org/clinical/NCT05257031. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*